FDA approves new drug for gout
On Dec. 22, the U.S. Food and Drug Administration (FDA) approved Zurampic (lesinurad) to treat high levels of uric acid in the blood (hyperuricemia)…
News
FDA changes blood donation policy
On Dec. 21, the U.S. Food and Drug Administration (FDA) changed its recommendation that men who have sex with men be indefinitely deferred from donating…
FDA approves new drug for PAH
On Dec. 22, the U.S. Food and Drug Administration (FDA) approved Uptravi (selexipag) tablets to treat adults with pulmonary arterial hypertension (PAH). Read more.
FDA approves new drugs
·On Dec. 16, the U.S. Food and Drug Administration (FDA) approved Basaglar (insulin glargine injection), a long-acting human insulin analog to improve glycemic control…
FDA approves new drugs
· On Dec. 8, the U.S. Food and Drug Administration (FDA) approved: · Vonvendi, von Willebrand factor (Recombinant), for use in adults 18 years…
FDA approves new treatment for multiple myeloma
On Nov. 30, the U.S. Food and Drug Administration (FDA) approved Empliciti (elotuzumab) in combination with two other therapies to treat people with multiple…
FDA approves new drugs
· On Nov. 16, the U.S. Food and Drug Administration (FDA) granted accelerated approval for Darzalex (daratumumab) to treat patients with multiple myeloma who…
FDA approves new treatment for advanced melanoma
On Nov. 10, the U.S. Food and Drug Administration (FDA) approved Cotellic (cobimetinib) to be used in combination with vemurafenib to treat advanced melanoma…
FDA approves new drug for severe asthma
On Nov. 4, the U.S. Food and Drug Administration (FDA) approved Nucala (mepolizumab) for use with other asthma medicines for the maintenance treatment of…
FDA approves new melanoma treatments
On Oct. 28, the U.S. Food and Drug Administration (FDA) expanded the approved use of Yervoy (ipilimumab) to include a new use as adjuvant…
FDA approves new drug for hyperkalemia
On Oct. 22, the U.S. Food and Drug Administration (FDA) approved eltassa (patiromer for oral suspension) to treat hyperkalemia. Read more.
FDA approves new drug for gout
On Dec. 22, the U.S. Food and Drug Administration (FDA) approved Zurampic (lesinurad) to treat high levels of uric acid in the…
FDA changes blood donation policy
On Dec. 21, the U.S. Food and Drug Administration (FDA) changed its recommendation that men who have sex with men be indefinitely deferred…
FDA approves new drug for PAH
On Dec. 22, the U.S. Food and Drug Administration (FDA) approved Uptravi (selexipag) tablets to treat adults with pulmonary arterial hypertension (PAH).…
FDA approves new drugs
·On Dec. 16, the U.S. Food and Drug Administration (FDA) approved Basaglar (insulin glargine injection), a long-acting human insulin analog to improve…
FDA approves new drugs
· On Dec. 8, the U.S. Food and Drug Administration (FDA) approved: · Vonvendi, von Willebrand factor (Recombinant), for use in adults…
FDA approves new treatment for multiple myeloma
On Nov. 30, the U.S. Food and Drug Administration (FDA) approved Empliciti (elotuzumab) in combination with two other therapies to treat people…
FDA approves new drugs
· On Nov. 16, the U.S. Food and Drug Administration (FDA) granted accelerated approval for Darzalex (daratumumab) to treat patients with multiple…
FDA approves new treatment for advanced melanoma
On Nov. 10, the U.S. Food and Drug Administration (FDA) approved Cotellic (cobimetinib) to be used in combination with vemurafenib to treat…
FDA approves new drug for severe asthma
On Nov. 4, the U.S. Food and Drug Administration (FDA) approved Nucala (mepolizumab) for use with other asthma medicines for the maintenance…
FDA approves new melanoma treatments
On Oct. 28, the U.S. Food and Drug Administration (FDA) expanded the approved use of Yervoy (ipilimumab) to include a new use…
FDA approves new drug for hyperkalemia
On Oct. 22, the U.S. Food and Drug Administration (FDA) approved eltassa (patiromer for oral suspension) to treat hyperkalemia. Read more.
Get your free access to the exclusive newsletter of American Nurse Journal and gain insights for your nursing practice.
NurseLine Newsletter
*By submitting your e-mail, you are opting in to receiving information from Healthcom Media and Affiliates. The details, including your email address/mobile number, may be used to keep you informed about future products and services.